Bristol-Myers Squibb Co. (BMY) intends to split its 83.1% holding in the Nutritional segment which operates under its subsidiary Mead Johnson and develops infant formulas such as Enfamil and other nutritional products. The move is aimed to enable the company to concentrate on its core biopharmaceutical business. The transaction is expected to be accretive to earnings beginning in 2010.  Under the terms of the deal, Bristol-Myers shareholders can exchange some, none or all of their shares of the company for shares of Mead Johnson common stock tax-free and at a discount. On completion, the exchange offer would enable Bristol-Myers to dispose of its entire holding interest in Mead Johnson.  For every $1 of Bristol-Myers stock exchanged, stockholders will get approximately $1.11 worth of Mead shares. The offer is set to expire on Dec 14, unless extended or terminated. Bristol-Myers owns 170 million shares of Mead Johnson. ...

Yesterday, GlaxoSmithKline (GSK) received some good news with the US Food and Drug Administration’s (FDA) approval of Votrient (pazopanib) for the treatment of patients with advanced renal cell carcinoma (RCC), a form of kidney cancer. However, the FDA approval does not come as a surprise to us as earlier this month the FDA’s Oncologic Drugs Advisory Committee (ODAC) had voted unanimously in favor of the drug.  The favorable recommendation was based on encouraging results from a phase III trial of Votrient, in which the drug reduced the risk of tumor progression or death by 54% compared to placebo, regardless of prior treatment. The overall median progression-free survival (PFS) was 9.2 months with Votrient and 4.2 months with placebo.  For both treatment naïve patients and those who received cytokine-based treatment, the median PFS was better with Votrient – 11.1 months versus 2.8 months with placebo, and 7.4 ...

For Immediate Release

Chicago, IL – October 21, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Biogen Idec (BIIB), Elan (ELN), UnitedHealth Group Inc. (UNH), Forest Laboratories, Inc. (FRX) and Cypress Biosciences (CYPB).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s AnalystBlog:

Biogen Reports Higher Earnings

Today morning, Biogen Idec (BIIB) reported third quarter earnings per share of $1.12, beating the Zacks Consensus Estimate of $1.02. The company reported earnings of 98 cents in the year-ago period. Revenues increased 3% to $1.12 billion, with Tysabri being the primary growth

...

This morning, Forest Laboratories, Inc. (FRX), reported earnings per share of 85 cents for the second quarter of fiscal 2010, in-line with the Zacks Consensus Estimate. Product sales increased 4% to $962.7 million. Although Lexapro sales declined 3.1% to $566 million, Namenda, which is approved for the treatment of moderate and severe Alzheimer’s disease, delivered sales of $275.3 million, recording a growth of 11.9% from the year-ago period. Improved patient access and increased promotional efforts should help keep Namenda sales strong. Bystolic, Forest’s beta-blocker for the treatment of hypertension, posted sales of $40.7 million. This was significantly higher than the year ago sales of $14.2 million. Contract revenue, consisting primarily of Benicar co-promotion income, increased 7.2% to $50.6 million. Forest’s most recent product launch, Savella, which is approved for the management of fibromyalgia, posted sales of $10.2 million. The product, which has been developed in ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Friday September 25, 2009

DrStockPick.com Stock Report!

PWRM, PFE, NVS

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II

...

In an attempt to takeover the European junk bonds after the financial crisis, Nycomed, one of the private equity-owned Swiss drugmaker has made a 4.5 billion Euros bid to purchase Solvay SA’s drug operations. The Zurich based company said that it this bid and takeover is finalized it will help them to reach their annual sales figures of $6 million which is why they have gone ahead and made such a high bid to buy Solvay’s pharmaceutical unit and operations. However, the Belgian conglomerate Solvay SA’s has not yet responded to the bid and has informed that they might take a little time to think about it and would not rush through the deal....

Lotus Pharmaceuticals, Inc. reported Q2 2009 net income of $4.8 million, or $0.10 per share. The company earned $ 2.2 million, or $0.05 per share, in the second quarter of 2008. Revenues totaled $13.6 million, down sharply from the $19.4 million reported in the second quarter of 2008.

Lotus Pharmaceuticals, Inc. was able to accomplish a doubling in net income despite the revenue drop due to increased margins. Gross margin ending the quarter was 57.9%. The company cut operating expenses by 63% on a year over year basis.

Dr. Zhongyi Liu, the CEO of Lotus Pharmaceuticals, Inc., said, “We are very pleased with our growth in sales quantities and gross margins of this quarter. Our pricing policy for 2009 has been adjusted accordingly due to the expected inflation contraction on the wholesale level nationally.”

Lotus Pharmaceuticals, Inc. is a manufacturer of pharmaceuticals and over the counter medicine, based on both

...

DrStockPick.com Stock Report!

Thursday July 30, 2009

**************************************************************

GSE Systems, Inc. (NYSE Amex - GVP), a leading global provider of real-time simulation and training solutions to the power, process, manufacturing and Government sectors, will hold a conference call on Monday, Aug. 10, 2009, at 4:30 p.m. Eastern Time to discuss results for the second quarter and mid-year 2009. Financial results will be issued in a press release after the close of the market the same day.

The Board of Directors of Sensient Technologies Corporation (NYSE: SXT) has declared a regular quarterly cash dividend on its common stock of $0.19 per share. The cash dividend will be paid on September 1, 2009, to shareholders of

...

Headquartered in Hayward, California, Aradigm Corp. engages in developing inhalation drug products that enhance the quality of life of patients with severe pulmonary disease. Founded in 1991, the company has a team of scientists, engineers, and clinical experts who have been at the forefront of development of advanced inhalation delivery products.

Aradigm Corp.’s team pioneered the AERx® iDMS pulmonary delivery of insulin used in Phase 3 clinical trials conducted by their partner Novo Nordisk. Today, with experience and expertise in inhalation delivery, Aradigm is positioning their company to develop a portfolio of their own products to treat patients with severe respiratory diseases. The company’s current pipeline includes products undergoing development by Aradigm, or in partnerships with others, for the treatment of cystic fibrosis, inhalation anthrax, and pulmonary arterial hypertension. Aradigm Corp. is also investigating the use of their technology for tobacco smoking cessation therapy.

Aradigm’s AERx pulmonary drug delivery platform demonstrated

...

We are presenting a list of companies which we believe are currently mispriced, based on our estimate of fair value, by the market. We develop our fair value ranges by projected free cash flow out one year and estimating an appropriate FCF multiple based on our assessment of risk and the strength of the balance sheet.

Cisco Systems [CSCO: 19.57, +0.84 (+4.48%)] Recent Price $17.04 Value Range 21.86 – $38.41 Cisco Systems, Inc. designs, manufactures and sells Internet protocol (IP)-based networking and other products related to the communications and information technology (IT) industry, and provides services associated with these products and their use. The Company provides a line of products for transporting data, voice, and video within buildings, across campuses, and around the world. Its products are designed to transform how people connect, communicate and collaborate. Cisco Systems, Inc.’s products, which include primarily routers, switches, and products that the

...